Regeneron, Bayer initiate DME drug Phase 3 trial
Led by Bayer Healthcare, the first Phase 3 trial VIVID-DME, in DME is also expected to be organized in Europe and Japan. However, the second trial will be
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.